Vantage Consulting Group’s DexCom DXCM Stock Holding History

Vantage Consulting Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-680	Closed	-$63K	–	512
2020 Q4	$63K	Buy	+680	New	+$60.7K	0.01%	363

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vantage Consulting Group's DXCM Position: Q1 2021 in Review

Vantage Consulting Group sold out of DexCom (DXCM) in Q1 2021, closing a stake of 680 shares — an estimated $63K sold.

Vantage Consulting Group first reported a position in DXCM in Q4 2020 and held it in 1 quarter. The position peaked at $63K in Q4 2020. 729 funds tracked by Wall St. Rank hold DXCM as of Q1 2021.

Vantage Consulting Group reported no remaining DexCom position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 680 DexCom shares in Q1 2021, an estimated $63K.
Vantage Consulting Group first reported a position in DexCom in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's DexCom position peaked at $63K in Q4 2020.
729 funds tracked by Wall St. Rank held DexCom as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.